# mRNA cancer vaccine clears a melanoma Phase 3 test

> Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value.

_Source: Moderna and Merck announcement, cross-checked with Reuters and STAT · 2026-08-20 · 5 min read · Verified against primary sources_

Canonical: https://iyu.app/e/moderna-merck-mrna-melanoma-phase3

## The 60-second version

Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value.

**Key points**

- The vaccine is designed from each tumor’s molecular features.
- The trial measured recurrence-free and distant-metastasis-free survival.
- A company-announced positive result is not proof that every patient is cured.

**Verdict.** This is a strong signal for personalized vaccines, not a cure headline.

## Full explainer


### What changed — mRNA cancer vaccine clears a melanoma Phase 3 test

Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value.


### Why it matters — The vaccine is designed from each tumor’s molecular features.

Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value. The vaccine is designed from each tumor’s molecular features. This is a strong signal for personalized vaccines, not a cure headline.


### Why it matters — The trial measured recurrence-free and distant-metastasis-free survival.

Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value. The trial measured recurrence-free and distant-metastasis-free survival. This is a strong signal for personalized vaccines, not a cure headline.


### Why it matters — A company-announced positive result is not proof that every patient is cured.

Moderna and Merck say their personalized mRNA vaccine with Keytruda met recurrence and distant-metastasis endpoints in melanoma, but fuller data still determine its clinical value. A company-announced positive result is not proof that every patient is cured. This is a strong signal for personalized vaccines, not a cure headline.

> This is a strong signal for personalized vaccines, not a cure headline.


## Primary sources

- [Moderna](https://www.modernatx.com/newsroom/news-and-media)
- [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-merck-vaccine-cuts-recurrence-spread-melanoma-raising-new-treatment-hope-2026-08-19/)
- [STAT](https://www.statnews.com/2026/08/19/moderna-merck-mrna-cancer-vaccine-melanoma-trial/)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._